1 North Waukegan Road
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Stock Symbol: ABBV
Stock Exchange: NYSE
People. Passion. Possibilities. Those three simple words mean everything at AbbVie, where patients always come first. So do cutting-edge science and innovation, which fuel our expanding pipeline as we take on the world's toughest health challenges in oncology, immunology, liver disease, women's health and beyond. Together, we strive to make a difference for patients around the world. For more visit: www.abbvie.com.
956 articles with AbbVie
AbbVie’s JAK inhibitor Rinvoq was approved by the U.S. Food and Drug Administration for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).
According to a regulatory filing, Saunders will walk away with $14.9 million in cash and $23.6 million in equity, mostly stock based on performance.
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in t...
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for elagolix
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2019.
Sales of Humira slid in Europe as AbbVie's cash cow continues to face competition from biosimilars that became available at the end of last year.
Despite the approval, Samsung Bioepis' Hadlima will not be available in the U.S. until 2023, due to licensing deals with AbbVie, the maker of Humira.
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
The M&A moves are expected to increase the oncology pipelines of both companies.
AbbVie, a research-based global biopharmaceutical company, will announce its second-quarter 2019 financial results on Friday, July 26 before the market opens.
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
CytomX Therapeutics, Inc. announced the second target selection by its partner AbbVie under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates.
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
AbbVie issued the following forms
Humira generates about 60% of AbbVie's annual revenue but is expected to lose patent protection in 2023.
Provides immediate scale and profitability to AbbVie's growth platform, excluding Humira, significantly expanding and diversifying its revenue base with new therapeutic areas, including Allergan's leading medical aesthetics business